As of March 31, 2024, our financial position was strong with 36.3% leverage, calculated as outstanding principal balance of our borrowings less cash and cash equivalents divided by the fair value of our real property, net investments in our unconsolidated joint venture partnerships, investments in real estate-related securities and debt-related investments not associated with the DST Program (determined in accordance with our valuation procedures). In addition, our consolidated portfolio was 94.8% occupied (95.3% leased) as of March 31, 2024 and is diversified across 99 properties totaling 20.1 million square feet across 33 geographic markets. Our properties contain a diverse roster of 416 commercial customers, large and small, and has an allocation based on fair value of real properties as determined by our NAV calculation of 38.0% residential, 35.9% industrial, 14.4% retail which is primarily grocery-anchored, 10.5% office and 1.2% other properties in adjacent sectors.
We believe that our cash on-hand, anticipated net offering proceeds, proceeds from our line of credit, and other financing and disposition activities should be sufficient to meet our anticipated future acquisition, operating, debt service, distribution and redemption requirements.
Cash Flows. The following table summarizes our cash flows for the following periods:
| | | | | | | | | | |
| | For the Three Months Ended March 31, | | | | |
(in thousands) | | 2024 | | 2023 | | $ Change | |
Total cash provided by (used in): | | | | | | | | | | |
Operating activities | | $ | 7,792 | | $ | (15,773) | | $ | 23,565 | |
Investing activities | | | (62,927) | | | 19,170 | | | (82,097) | |
Financing activities | | | 55,398 | | | 20,170 | | | 35,228 | |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | | | (6) | | | — | | | (6) | |
Net increase in cash, cash equivalents and restricted cash | | $ | 257 | | $ | 23,567 | | $ | (23,310) | |
Net cash provided by operating activities increased by $23.6 million for the three months ended March 31, 2024, compared to the same period in 2023, primarily due to the $23.7 million settlement of the 2022 performance participation allocation in cash in January 2023.
Net cash used in investing activities increased by $82.1 million for the three months ended March 31, 2024, compared to the same period in 2023, primarily due to a decrease in proceeds from disposition of real estate property of $53.7 million and an increase in investments in debt-related investments and unconsolidated joint venture partnerships of $40.7 million. These drivers were partially offset by a decrease in real estate property acquisition activity of $14.7 million.
Net cash provided by financing activities increased by $35.2 million for the three months ended March 31, 2024, compared to the same period in 2023, primarily due to an increase in net borrowing activity of $18.7 million and an increase in net offering activity from our DST Program and public offering of $15.4 million.
Capital Resources and Uses of Liquidity
In addition to our cash and cash equivalents balances available, our capital resources and uses of liquidity are as follows:
Line of Credit and Term Loans. As of March 31, 2024, we had an aggregate of $1.7 billion of commitments under our unsecured credit agreement, including $900.0 million under our line of credit and $800.0 million under our two term loans. As of that date, we had: (i) $357.1 million outstanding under our line of credit; and (ii) $800.0 million outstanding under our term loans. The weighted-average effective interest rate across all of our unsecured borrowings is 4.31%, which includes the effect of the interest rate swap and cap agreements related to $950.0 million in borrowings under our line of credit and our term loans.
As of March 31, 2024, the unused and available portions under our line of credit were $542.9 million and $357.5 million, respectively. Our $900.0 million line of credit matures in November 2025, and may be extended pursuant to two six-month extension options, subject to certain conditions, including the payment of extension fees. One $400.0 million term loan matures in November 2026, with no extension option available. Our other $400.0 million term loan matures in January 2027, with no extension option available. Our line of credit borrowings are available for general corporate purposes, including but not limited to the refinancing of other debt, payment of redemptions, acquisition and operation of permitted investments. Refer to “Note 5 to the Condensed Consolidated Financial Statements” for additional information regarding our line of credit and term loans.